Trials / Unknown
UnknownNCT05332210
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HBM9161 Injection (680mg) | HBM9161 Injection |
Timeline
- Start date
- 2022-06-30
- Primary completion
- 2023-09-30
- Completion
- 2023-12-30
- First posted
- 2022-04-18
- Last updated
- 2023-03-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05332210. Inclusion in this directory is not an endorsement.